Proprietary Formulations and Drug Candidates
Pharmaceutical Candidates Designed to Address 5 Major Clinical Indications
Pipeline of Proprietary Drug Candidates
Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization
These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
Trunerox™ – 10% CBD (100 mg/ml Cannabidiol)
Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption
Marketing authorization is expected during late 2023/early 2024 in Brazil and other South American markets. Trunerox will be available with accessible pricing, utilizing the company’s vertical integration.
Contact Us
